Disruptive Therapies for the long-term relief of Osteoarthritis Pain

Fact Sheet

Project Information

**Arth-Alleve**
Grant agreement ID: 101045226

**Funded under**
European Research Council (ERC)

**DOI**
[10.3030/101045226](https://doi.org/10.3030/101045226)

**Start date**
1 March 2023

**End date**
29 February 2028

**Total cost**
€ 1 998 885,00

**EU contribution**
€ 1 998 885,00

**Coordinated by**
NATIONAL UNIVERSITY OF IRELAND GALWAY
Ireland

Project description

**Neurotoxin for osteoarthritis treatment**

Osteoarthritis is a degenerative condition associated with breakdown of collagen in the cartilage of the joints that cushion the bones. It is characterised by debilitating pain that is conventionally managed by non-steroid anti-inflammatory drugs and opioids. However, these interventions are not always effective or lead to side effects, necessitating alternative therapies. The ERC-funded Arth-Alleve project aims to address this unmet medical need through the development of a non-pharmacological therapy. The strategy is based on using neurotoxin molecules to block the nerves associated with osteoarthritis pain. These will be anchored to hydrogel particles to
prevent them from escaping into the circulation, providing only localised effect and contributing to a significant improvement in the quality of life for patients.
Activity type

Higher or Secondary Education Establishments

Links

Contact the organisation 🗣️  Website 🗣️
Participation in EU R&I programmes 🗣️
HORIZON collaboration network 🗞️

Other funding

€ 0,00

EC signature date 9 December 2022
Last update: 16 December 2022

Permalink: https://cordis.europa.eu/project/id/101045226

European Union, 2023